

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA**

**Rucaparib for maintenance treatment of recurrent epithelial ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1435]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- |    |  |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

|  |
|--|
| Consultees commented that ovarian cancer is more common in women over 50 and cancer is considered a disability under the Equality Act 2010. Therefore age, gender and disability are all relevant protected characteristics for the purpose of this appraisal. |
|--|

- |    |  |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

|   |
|---|
| Although the prevalence of ovarian cancer is more common in women over the age of 50 this is not something that can be addressed in a technology appraisal. The committee will consider the impact of any disabilities when it makes its recommendations. |
|---|

- |    |   |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

|  |
|--|
| No changes to the draft scope has been made. |
|--|

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

**Approved by Associate Director (name):** .....Janet Robertson .....

**Date:** 15/11/2018